Statistics for Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors

Total visits

views
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors 0

Total visits per month

views
September 2025 0
October 2025 0
November 2025 0
December 2025 0
January 2026 0
February 2026 0
March 2026 0